A total of 567 virtual patient simulations were performed by scanning CD19‐positive expression levels, CD19 antigen surface densities per tumour cells, the initial tumour mass and the tumour location using Lonca dosing from the LOTIS‐2 study (150 μg/kg every 3 weeks for the first two cycles, followed by 75 μg/kg for subsequent cycles) (Figure 3; Figure S2). The gene discussed is CD19; the disease is neoplasm.